Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy [clinicaltrials:NCT00115206]

Bio2RDF uri

Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy [clinicaltrials:NCT00115206]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT00115206

Bio2RDF identifier

NCT00115206

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00115206

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00115206

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:d942c8692d257084abf3ac87279faff6

brief summary [clinicaltrials_vocabulary:brief-summary]

The purpose of this stu ...... ut Neulasta® (pegfilgrastim).

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Neulasta® in Subjects With Adv ...... er (NSCLC) During Chemotherapy

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Quality of Life [clinicaltrials_resource:0cec3c1de6833cdfdc9a2894bb25e872]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Quality of Life [clinicaltrials_resource:5ea57d49fa449cfef4f6f82259f8b9c8]

completion date [clinicaltrials_vocabulary:completion-date]

2004-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00115206 [clinicaltrials_resource:9cba5854d55c64f2a0c548b195f48e04]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2005-06-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

intervention [clinicaltrials_vocabulary:intervention]

Neulasta® (pegfilgrastim) [clinicaltrials_resource:85532478769eaf0bf4ce3c21626a788f]

keyword [clinicaltrials_vocabulary:keyword]

Amgen

http://www.w3.org/2001/XMLSchema#string

Chemotherapy

http://www.w3.org/2001/XMLSchema#string

Fever

http://www.w3.org/2001/XMLSchema#string

NSCLC

http://www.w3.org/2001/XMLSchema#string

Neulasta®

http://www.w3.org/2001/XMLSchema#string

Neutropenia

http://www.w3.org/2001/XMLSchema#string

Non Small Cell Lung Cancer

http://www.w3.org/2001/XMLSchema#string

Quality of Life

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2009-04-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Amgen [clinicaltrials_resource:c142e310cf1889900ac13cc74784585c]

link [clinicaltrials_vocabulary:link]

AmgenTrials clinical trials website [clinicaltrials_resource:293bf329518cc6e3e14cef61046204f4]

Notice regarding posted summaries of trial results [clinicaltrials_resource:33ac1edbf4569ba5f7763920dd01b141]

To access clinical trial results information click on this link [clinicaltrials_resource:4d7ad53af8a12d7594d4c8c00c7acdb4]

FDA-approved Drug Labeling [clinicaltrials_resource:88d375faadfa5126ab3c17239aabf26a]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00115206

http://www.w3.org/2001/XMLSchema#string

official title [clinicaltrials_vocabulary:official-title]

A Pilot Study of the Effects o ...... n Subjects With Advanced NSCLC

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

20,020,121

http://www.w3.org/2001/XMLSchema#integer

overall official [clinicaltrials_vocabulary:overall-official]

MD [clinicaltrials_resource:8377b1b1ffe5d6f5b2ef6f02a1bd0650]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:77fa11db9aea1d8cd0ff35db5bc538f2]

phase [clinicaltrials_vocabulary:phase]

Phase 4 [clinicaltrials_resource:ec41833bc88cd90619c4d85c549688bd]

responsible party [clinicaltrials_vocabulary:responsible-party]

Global Development Leader, Amgen Inc. [clinicaltrials_resource:1f5972c898ba06efef08f63eea6b77f7]

source [clinicaltrials_vocabulary:source]

Amgen [clinicaltrials_resource:c142e310cf1889900ac13cc74784585c]

start date [clinicaltrials_vocabulary:start-date]

2002-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00115206 study design [clinicaltrials_resource:8f76e3a3851a558353e00f3134ff0458]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00115206

verification date [clinicaltrials_vocabulary:verification-date]

2009-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00115206

http://www.w3.org/2001/XMLSchema#string

title

Neulasta® in Subjects With Adv ...... er (NSCLC) During Chemotherapy

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Neulasta® in Subjects With Adv ...... y [clinicaltrials:NCT00115206]

@en